Related references
Note: Only part of the references are listed.HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
Ryan Shea Ying Cong Tan et al.
BMC MEDICINE (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Caterina Marchio et al.
SEMINARS IN CANCER BIOLOGY (2021)
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini et al.
NPJ BREAST CANCER (2021)
Biomarker Analysis of the Phase III NALA Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2021)
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
Carsten Denkert et al.
LANCET ONCOLOGY (2021)
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Elisa Agostinetto et al.
CANCERS (2021)
Results of a Randomized Phase IIb Trial of Nelipepimut-S thorn Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
G. Travis Clifton et al.
CLINICAL CANCER RESEARCH (2020)
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
Sonia Pernas et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma
Eun Kyung Kim et al.
PLOS ONE (2017)
The paradoxical functions of EGFR during breast cancer progression
Remah Ali et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini et al.
EMBO REPORTS (2015)
National Guidelines and Level of Evidence: Comments on Some of the New Recommendations in the American Society of Clinical Oncology and the College of American Pathologists Human Epidermal Growth Factor Receptor 2 Guidelines for Breast Cancer
Emad A. Rakha et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Aline Appert-Collin et al.
FRONTIERS IN PHARMACOLOGY (2015)
Updated UK Recommendations for HER2 assessment in breast cancer
Emad A. Rakha et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
HER2 in Breast Cancer: A Review and Update
Uma Krishnamurti et al.
ADVANCES IN ANATOMIC PATHOLOGY (2014)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2014)
Computerized Texture Analysis of Persistent Part-Solid Ground-Glass Nodules: Differentiation of Preinvasive Lesions from Invasive Pulmonary Adenocarcinomas
Hee-Dong Chae et al.
RADIOLOGY (2014)
Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis
Hedyeh Shafi et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast
Andrew H. S. Lee et al.
HISTOPATHOLOGY (2012)
HER2 testing in gastric cancer: a practical approach
Josef Rueschoff et al.
MODERN PATHOLOGY (2012)
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue
Steven J. Potts et al.
LABORATORY INVESTIGATION (2012)
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
A. Noske et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
High False- Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study
David J. Dabbs et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Achieving 95% Cross-Methodological Concordance in HER2 Testing Causes and Implications of Discordant Cases
Erin E. Grimm et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens
Tommaso Susini et al.
GYNECOLOGIC ONCOLOGY (2010)
Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories
Frederick L. Baehner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?
Pradip De et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle Biopsies
Annette Lebeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab
N Dybdal et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Updated recommendations for HER2 testing in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience
S Paik et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
PC Roche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Share Paper
